Abasaglar® (insulin glargin): HbA1c resultat hos patienter med diabetes typ 2

ABASAGLAR® (insulin glargine) : HbA1c Results in Patients in Patients with Type 2 Diabetes Mellitus

In patients with T2DM, at week 24, treatment with Abasaglar provided a LSM reduction in HbA1c that was noninferior to that achieved with Lantus.

Adult patients with T2DM participated in the ELEMENT-2 study, a double-blind, active-controlled study, to evaluate the glucose lowering effect of once-daily Abasaglar plus OAMs compared with that of Lantus administered once daily along with OAMs. Patients were

• insulin naïve (~60%) and had failed to achieve adequate glycemic control on at least 2 OAMs, or

• already on Lantus with at least 2 OAMs with adequate or inadequate glycemic control (~40%).¹

Results

Characteristics of the 759 randomized patients included

• 78.5% white

• 50% male

• a mean age of approximately 59 years

• a mean BMI of approximately 32 kg/m², and

• 67.5% with a GFR >90 mL/min/1.73m².^1,2

A total of 3 patients randomized to Abasaglar did not receive study drug and were not included in efficacy analysis.²

At week 24, treatment with Abasaglar provided a LSM reduction in HbA1c that was noninferior to that achieved with treatment with Lantus (Table 1).¹

Table 1. Efficacy Results in Adult Patients With T2DM - ELEMENT-2 Study¹

Abbreviations: Abasaglar = Abasaglar® (insulin glargine) 100 units/mL; ELEMENT-2 = a prospEctive, randomized, doubLE-blind coMparison of a long-acting basal insulin analog LY2963016 to Lantus® in adult patiENTs with type 2 diabetes mellitus; HbA1c = glycated hemoglobin; Lantus = Lantus® (insulin glargine) 100 units/mL; LOCF = last observation carried forward; LSM = least squares mean; OAM = oral antihyperglycemic medication; T2DM = type 2 diabetes mellitus.

^a Data from LOCF; p>.05 for all treatment comparisons.

References

1. Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17(8):734-741. http://dx.doi.org/10.1111/dom.12482

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

BMI = body mass index

ELEMENT-2 = a prospEctive, randomized, doubLE-blind coMparison of a long-acting basal insulin analog LY2963016 to Lantus® in adult patiENTs with type 2 diabetes mellitus

GFR = glomerular filtration rate

HbA1c = glycated hemoglobin

Lantus = Lantus® (insulin glargine) 100 units/mL

OAM = oral antihyperglycemic medication

T2DM = type 2 diabetes mellitus